Sarcopenia associated with gastric cancer

Sierżęga, Marek; Chrzan, Robert

doi:10.1002/jso.25744

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a universally accepted definition of sarcopenia has yet been reached for decades. Nevertheless, with sarcopenia gradually being used in other relevant systems apart from skeletal muscle system such as cardiovascular disease ( Izumida and Imamura, 2020 ), cancer (gastric cancer ( Sierzega and Chrzan, 2019 )), endocrine system (diabetes ( Fukuoka et al, 2019 ), the European Working Group Sarcopenia (EWGSOP)) published progress and updates of the definition of sarcopenia in the Age and Aging, aiming to achieve a consensus definition of it. Cruz-Jentoft et al recognized sarcopenia as a new geriatric syndrome ( Cruz-Jentoft et al, 2010b ), though such definition has recently been progressed and updated by the EWGSOP in 2010 ( Cruz-Jentoft et al, 2010a ), revised by the EWGSOP2 in 2018 ( Cruz-Jentoft et al, 2019 ), and supported by the Asian Working Group on Sarcopenia (AWGS) in 2014 ( Chen et al, 2014 ).…”

Section: Sarcopeniamentioning

confidence: 99%

Cellular Senescence in Sarcopenia: Possible Mechanisms and Therapeutic Potential

Yang

Xie

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Aging promotes most degenerative pathologies in mammals, which are characterized by progressive decline of function at molecular, cellular, tissue, and organismal levels and account for a host of health care expenditures in both developing and developed nations. Sarcopenia is a prominent age-related disorder in musculoskeletal system. Defined as gradual and generalized chronic skeletal muscle disorder, sarcopenia involves accelerated loss of muscle mass, strength and function, which is associated with increased adverse functional outcomes and evolutionally refers to muscle wasting accompanied by other geriatric syndromes. More efforts have been made to clarify mechanisms underlying sarcopenia and new findings suggest that it may be feasible to delay age-related sarcopenia by modulating fundamental mechanisms such as cellular senescence. Cellular senescence refers to the essentially irreversible growth arrest mainly regulated by p53/p21CIP1 and p16INK4a/pRB pathways as organism ages, possibly detrimentally contributing to sarcopenia via muscle stem cells (MuSCs) dysfunction and the senescence-associated secretory phenotype (SASP) while cellular senescence may have beneficial functions in counteracting cancer progression, tissue regeneration and wound healing. By now diverse studies in mice and humans have established that targeting cellular senescence is a powerful strategy to alleviating sarcopenia. However, the mechanisms through which senescent cells contribute to sarcopenia progression need to be further researched. We review the possible mechanisms involved in muscle stem cells (MuSCs) dysfunction and the SASP resulting from cellular senescence, their associations with sarcopenia, current emerging therapeutic opportunities based on targeting cellular senescence relevant to sarcopenia, and potential paths to developing clinical interventions genetically or pharmacologically.

show abstract

Section: Sarcopeniamentioning

confidence: 99%

Cellular Senescence in Sarcopenia: Possible Mechanisms and Therapeutic Potential

Yang

Xie

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Many studies have confirmed that skeletal muscle mass is independently associated with postoperative complications in gastric cancer patients. Therefore, numerous studies suggest early screening of skeletal muscle mass in patients with gastric cancer, and supportive nutritional treatment should be given to those patients with skeletal muscle depletion (4)(5)(6). The traditional detection methods used to measure skeletal muscle mass, such as CT scans, are costly and complex.…”

Section: Introductionmentioning

confidence: 99%

Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass for predicting postoperative complications in patients undergoing gastric cancer surgery

Gao¹,

Liang²,

Qian³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Gastric cancer patients usually suffer from skeletal muscle depletion. The serum creatinine/ cystatin C ratio (CCR) is a new, simple tool that could serve as a biomarker of skeletal muscle mass. This study explored the ability of the preoperative CCR to predict postoperative complications in patients with gastric cancer.Methods: A total of 309 patients with gastric cancer who were undergoing surgery were enrolled in this study. Univariate analyses were conducted to determine the potential risk factors for postoperative complications, and multivariate analyses were used to determine the independent influencing factors of postoperative complications. A receiver operating characteristic curve was conducted to identify the optimal cutoff value of the CCR. Patients were divided into two groups according to the critical value to investigate the relationship between the CCR and postoperative complications.Results: Postoperative complications occurred in 87 patients. Multivariate analysis suggested that age, red blood cell level, lymphocyte count, cystatin C, CCR, and N factor were independent risk or protective factors for postoperative complications (P<0.001). The optimal cutoff value of the preoperative CCR was 7.117. Compared with the high preoperative CCR group, patients with a low preoperative CCR were more likely to have both mild complications (P<0.001) and major complications (P<0.001). Conclusions:The preoperative CCR can effectively predict postoperative complications in gastric cancer patients after surgery.

show abstract

Sarcopenia associated with gastric cancer

Cited by 2 publications

References 6 publications

Cellular Senescence in Sarcopenia: Possible Mechanisms and Therapeutic Potential

Cellular Senescence in Sarcopenia: Possible Mechanisms and Therapeutic Potential

Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass for predicting postoperative complications in patients undergoing gastric cancer surgery

Contact Info

Product

Resources

About